Clarissa Parker to Carcinoma, Non-Small-Cell Lung
This is a "connection" page, showing publications Clarissa Parker has written about Carcinoma, Non-Small-Cell Lung.
Connection Strength
1.419
-
Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol. 2009 Jul 10; 27(20):3284-9.
Score: 0.184
-
A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization. Adv Exp Med Biol. 2014; 799:85-117.
Score: 0.127
-
Mind-mapping for lung cancer: towards a personalized therapeutics approach. Adv Ther. 2011 Mar; 28(3):173-94.
Score: 0.104
-
A multicenter phase II trial of carboplatin and cetuximab for treatment of advanced nonsmall cell lung cancer. Cancer Invest. 2010 Feb; 28(2):208-15.
Score: 0.097
-
The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected non-small cell lung cancer. J Thorac Oncol. 2008 Feb; 3(2):145-51.
Score: 0.084
-
Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program. Lung Cancer. 2006 Sep; 53(3):331-7.
Score: 0.075
-
Phase I/II study of gemcitabine and exisulind as second-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2006 Mar; 1(3):218-25.
Score: 0.074
-
A phase II trial of weekly paclitaxel and gemctiabine infused at a constant rate in patients with advanced non-small cell lung cancer. Lung Cancer. 2005 Mar; 47(3):413-9.
Score: 0.069
-
Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer. Lung Cancer. 2005 Feb; 47(2):253-9.
Score: 0.068
-
Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial. J Clin Oncol. 2004 Nov 01; 22(21):4341-50.
Score: 0.067
-
Duration of therapy in advanced, metastatic non-small-cell lung cancer. Clin Adv Hematol Oncol. 2003 Jan; 1(1):33-8.
Score: 0.059
-
Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2011 Aug; 6(8):1418-25.
Score: 0.054
-
Optical detection of buccal epithelial nanoarchitectural alterations in patients harboring lung cancer: implications for screening. Cancer Res. 2010 Oct 15; 70(20):7748-54.
Score: 0.051
-
The role of induction therapy in the management of resectable non-small cell lung cancer. Cancer Control. 2000 Jan-Feb; 7(1):45-55.
Score: 0.048
-
Combined-modality therapy in the nonsurgical management of unresectable stage III non-small cell lung cancer. Curr Opin Pulm Med. 1999 Jul; 5(4):194-200.
Score: 0.046
-
Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. J Thorac Oncol. 2007 Sep; 2(9):845-53.
Score: 0.041
-
Combined analysis of molecular and clinical predictors of gefitinib activity in advanced non-small cell lung cancer: epidermal growth factor receptor mutations do not tell the whole story. J Thorac Oncol. 2006 Jan; 1(1):52-60.
Score: 0.036
-
A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer. Ann Oncol. 2006 Jan; 17(1):104-9.
Score: 0.036
-
Clinical evaluation and staging of patients who have lung cancer. Hematol Oncol Clin North Am. 2005 Apr; 19(2):219-35, v.
Score: 0.035
-
Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol. 2004 Dec 01; 22(23):4837-45.
Score: 0.034
-
The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer. 2003 Aug 15; 98(4):779-88.
Score: 0.031